M.A. - LEK A.M.Maciejowscy SC.
About M.A. - LEK A.M.Maciejowscy SC.
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
8
Biogen
2
Celgene
2
Merck KGaA, Darmstadt, Germany
2
Actelion
1
Genentech, Inc.
1
Janssen Research & Development, LLC
1
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
1
SK Life Science, Inc.
1
Clinical Trials at M.A. - LEK A.M.Maciejowscy SC.
During the past decade, M.A. - LEK A.M.Maciejowscy SC. conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 8 clinical trials were completed, i.e. on
average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 5 clinical trials were completed. i.e. 83.3%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
2011-08-31
2022-12-31
Completed
821
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
2011-09-20
2022-12-30
Completed
835
An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
2013-03-28
2018-09-04
Completed
225
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
2013-08-01
2016-03-01
Completed
419
A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
2013-07-31
2021-10-31
Completed
437
Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
2014-02-20
2021-12-23
Completed
85
Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
2014-12-03
2016-12-22
Completed
1,346
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
2015-10-16
2023-01-05
Completed
2,350
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "M.A. - LEK A.M.Maciejowscy SC." #1 sponsor was "Hoffmann-La Roche" with 8 trials, followed by "Biogen" with 2 trials
sponsored, "Celgene" with 2 trials sponsored, "Merck KGaA, Darmstadt, Germany" with 2 trials sponsored and "Actelion"
with 2 trials sponsored. Other sponsors include -1 different institutions and
companies that sponsored additional 9 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "M.A. - LEK A.M.Maciejowscy SC."
#1 collaborator was "Chugai Pharmaceutical" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were
collaborators in the rest 1 trials.
Clinical Trials Conditions at M.A. - LEK A.M.Maciejowscy SC.
According to Clinical.Site data, the most researched conditions in "M.A. - LEK A.M.Maciejowscy SC." are
"Multiple Sclerosis" (10 trials), "Relapsing Multiple Sclerosis" (2 trials), "Alzheimer's Disease" (1 trials), "Focal Onset Seizures" (1 trials) and "Multiple Sclerosis, Primary Progressive" (1 trials). Many other conditions were trialed in "M.A. - LEK A.M.Maciejowscy SC." in a lesser frequency.
Clinical Trials Intervention Types at M.A. - LEK A.M.Maciejowscy SC.
Most popular intervention types in "M.A. - LEK A.M.Maciejowscy SC." are "Drug" (19 trials) and "Other" (2 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (9 trials), "Ocrelizumab" (6 trials), "Interferon beta-1a" (3 trials), "Antihistamine" (2 trials) and "Interferon beta-1a-matching placebo" (2 trials). Other intervention names were less common.
Clinical Trials Genders at M.A. - LEK A.M.Maciejowscy SC.
The vast majority of trials in "M.A. - LEK A.M.Maciejowscy SC." are
18 trials for "All" genders and 1 trials for "Female" genders.
Clinical Trials Status at M.A. - LEK A.M.Maciejowscy SC.
Currently, there are NaN active trials in "M.A. - LEK A.M.Maciejowscy SC.".
undefined are not yet recruiting,
5 are recruiting,
2 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 10 completed trials in M.A. - LEK A.M.Maciejowscy SC.,
undefined suspended trials,
and 2 terminated clinical trials to date.
Out of the total trials that were conducted in M.A. - LEK A.M.Maciejowscy SC., 1 "Phase 1"
clinical trials were conducted, 4 "Phase 2" clinical
trials and 12 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 2 trials, and there were
also 0 trials that are defined as “Not Applicable".